We Are Patient-Driven

A partnership in research discovery, innovation, and patient engagement

CANet is a Pan-Canadian multidisciplinary and multi-sectoral research and development network of investigators, well-positioned industry partners, patients, caregivers, and healthcare providers focused on arrhythmia research, technology development and commercialization, and digital transformation activities.

Millions of Canadians experience irregular heart rhythms, known as arrhythmias. Arrhythmias can cause sudden cardiac death, which kills 40,000 Canadians a year. Sudden Cardiac Death is projected to be the leading cause of morbidity and mortality in Canada by 2020.

Patients Engaged Across All Network Activites

From governance to research to disease management, patients are co-leaders across our Network.

We ensure patient partnership, involvement, and acceptability throughout the research cycle; from conception to execution, to implementation and evaluation, lead to outcomes allowing patients to co-manage their arrhythmia disorders and help produce both economic and social benefits for Canada.

To learn more about our research and CANet-funded projects, click here.

Network Investigators
Active HQP Trainees
Partner Matching Funds


Total Patients Enrolled In Research Programs


Our Research

With investigators across Canada, our Network conducts research under three broad themes:

  • Technological innovations to improve the treatment of arrhythmia conditions
  • Innovative, safe and effective treatments to prevent sudden cardiac death, halt the progression of atrial fibrillation and related illness and death and prevent disabling syncope
  • Effective solutions to promote a sustainable health system by empowering patients to manage their conditions

Sudden Cardiac Death is projected to be the leading cause of morbidity and mortality in Canada by 2020

CANet’s strategy is to invent, prove, and implement innovative solutions to achieve its vision.

Learn more about who we are, our goals, and the impacts we’re making, click here.